Before launching its COVID-19 test, which generated most of Co-Diagnostics' revenues in 2020, the firm's sales primarily came from mosquito-borne virus testing.
For the year ended Dec. 31, 2020, the firm reported revenues of $8.5 million compared to $19.2 million in 2019, beating the Wall Street estimate of $8.3 million.
The immune profiling company is looking to expand its functional genomics capabilities to more directly inform immune therapy development and application.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.